Pharmaceutical Technology

JULY 29, 2022

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.

Manufacturing 130

Manufacturing Vaccination Vaccine Packaging 130

Pharmaceutical Technology

NOVEMBER 22, 2022

Despite China producing a significant proportion of the world’s API supply (mostly small molecule), it manufactures relatively few biosimilar and innovator drugs and no cell and gene therapies for the western markets of Europe and the US despite investments and an increasing number of startups to improve innovative manufacture.

Manufacturing 162

Manufacturing Gene Therapy Gene Contract Manufacturing 162

Pharmaceutical Technology

MAY 23, 2023

Croda Pharma has entered a strategic collaboration deal with Botanical Solution Inc (BSI) to expedite the production of sustainable pharmaceutical-grade vaccine adjuvant QS-21. Croda Pharma and BSI will share their knowledge to bring QS-21 to market from quillaja Saponaria plant cell culture, which is made from the soap bark tree. “The

Production 240

Production Vaccination Vaccine Life Science 240

Roots Analysis

AUGUST 16, 2023

The success of COVID-19 vaccines paved the path for mRNA-based drug products. However, synthesis and manufacturing of mRNA is fraught with several challenges as the production of such biomolecules is complex, cost intensive, requires specialized expertise and dedicated equipment.

Contract Manufacturing 52

Contract Manufacturing Manufacturing Marketing RNA 52

Pharmaceutical Technology

NOVEMBER 21, 2022

RVAC Medicines has signed a master research partnership agreement with the Agency for Science, Technology and Research (A*STAR) for analysing and developing solutions to build messenger ribonucleic acid (mRNA) manufacturing and analytics expertise in Singapore. Topic sponsors are not involved in the creation of editorial content.

Manufacturing 130

Manufacturing Medicine Vaccination Vaccine 130

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

Pharmaceutical Technology

DECEMBER 12, 2022

In this last 2022 edition of the series, which started in June , Pharmaceutical Technology is tracking major trial announcements and decisions by regulators and reimbursement agencies that have occurred since mid-October, as well as their potential impact on manufacturing plans. Iomab-B met the durable complete remission endpoint.

Manufacturing 147

Manufacturing Drugs Packaging Packaging 147

BioPharma Reporter

JUNE 15, 2021

Ocugen has chosen Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVID-19 vaccine candidate COVAXIN, ready for potential commercial manufacture for the US and Canadian markets.

Manufacturing 105

Manufacturing Vaccination Vaccine Marketing 105

Fierce Pharma

SEPTEMBER 13, 2023

. | Moderna CEO Stéphane Bancel is optimistic that the company will beat the low end of its $6 billion to $8 billion COVID vaccine sales estimate for 2023. But his optimism comes as Moderna reportedly eyes manufacturing cuts as it shifts to an endemic market response.

Vaccination 91

Vaccination Vaccine Marketing Development 91

Pharmaceutical Technology

MAY 16, 2023

Bavarian Nordic has completed the acquisition of Emergent BioSolutions ’ travel vaccine portfolio for an upfront payment of $274m, with the potential for the total value to rise to $384m. Following the completion of the deal, Bavarian Nordic now boasts the only oral vaccine licensed by the U.S.

Vaccination 130

Vaccination Vaccine Licensing Licensing 130

World of DTC Marketing

DECEMBER 29, 2020

OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The coronavirus vaccines, however, took less than a year.

Vaccination 307

Vaccination Vaccine Development Clinical Trials 307

Pharmaceutical Technology

DECEMBER 8, 2022

5-adapted bivalent Covid-19 vaccine for usage in children aged six months to four years. The vaccine is indicated for use as a third 3µg dose in the three-dose initial regimen for children of this age group. Earlier this month, the companies sought FDA EUA for the Omicron-adapted vaccine for use in children aged below five years.

Vaccination 246

Vaccination Vaccine Manufacturing Marketing 246

Pharmaceutical Technology

MAY 26, 2023

The immuno-oncology market continues to evolve as treatments establish their presence across different types of cancer, having seen approvals in multiple indications in the past decade. GlobalData separates immuno-oncology treatments into six broad classes, which include bispecific antibodies, cancer vaccines, and cell therapies.

Marketing 264

Marketing Vaccination Vaccine Development 264

Pharmaceutical Technology

APRIL 4, 2023

Indian pharma manufacturing continues to be the backbone of drug supplies worldwide, and GlobalData analysis suggests US overreliance on the country for generic drug supply. Pharma manufacturing facilities in Andhra Pradesh and Telangana accounted for 22.5% © GlobalData. © GlobalData. ©GlobalData.

Manufacturing 130

Manufacturing Generic Drugs Contract Manufacturing Production 130

pharmaphorum

MARCH 10, 2021

The rollout of the US COVID-19 vaccination programme slowed up this week because manufacturing delays mean no new doses of the recently approved Johnson & Johnson vaccine are available. doses of the Pfizer/BioNTech and Moderna vaccine to states, tribes and territories, with another 2.7 of the adult population.

Manufacturing 108

Manufacturing Vaccination Vaccine Pharmacy 108

Pharmaceutical Technology

APRIL 24, 2023

Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. Biologics are costly to produce and sell, and the more recent modalities, such as cell and gene therapies, can be difficult to manufacture. According to a Brookings study, the US has always been a global leader in the sector.

Contract Manufacturing 130

Contract Manufacturing Manufacturing Protein Sales 130

Pharmaceutical Technology

SEPTEMBER 8, 2022

Find the leading API biologics companies in contract marketing. Pharmaceutical Technology has listed some of the top API biologics companies in contract marketing based on our intel, insights and decades-long experience in the sector. What is driving the biologics API manufacturing services industry.

Gene 100

Gene Marketing Vaccination Vaccine 100

Pharmaceutical Technology

AUGUST 17, 2022

On August 8, Pfizer and Valneva announced the initiation of a Phase III study with their Lyme disease vaccine , bringing the prospect of an injection to prevent the condition disease one step closer to reality. This means that the vaccine works against multiple serotypes of the disease, she explains. A one-size-fits-all approach.

Vaccination 299

Vaccination Vaccine Bacteria Protein 299

XTalks

MAY 28, 2024

In a move signaling a major shift in influenza prevention strategies, CSL Seqirus, a global leader in flu vaccines, has transitioned from quadrivalent to trivalent formulations for the upcoming 2024/25 flu season in the US.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

BioPharma Reporter

SEPTEMBER 19, 2023

The contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies has completed a UK manufacturing facility for the production of advanced therapies including viral gene therapies, oncolytic viruses and viral vaccines for use in clinical trials.

Manufacturing 98

Manufacturing Gene Therapy Clinical Trials Clinical Trials 98

Roots Analysis

MARCH 9, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. Biopharmaceutical Excipient Manufacturing Market. Biopharmaceutical Excipient Manufacturing Market.

Manufacturing 52

Manufacturing Marketing Contract Manufacturing Protein 52

Pharmaceutical Technology

JUNE 13, 2023

This will allow the Swiss company to begin ramping up its drug substance manufacturing process with its sister company FinVector Oy in Kuopio, Finland ahead of its planned product launch. Finvector Oy is a Finnish biopharmaceutical company that specialises in current Good Manufacturing Practice (cGMP) manufacturing.

Gene Therapy 246

Gene Therapy Manufacturing Gene FDA Approval 246

Pharmaceutical Technology

APRIL 27, 2023

The successful development and deployment of the mRNA-based COVID-19 vaccines has catalysed the biopharma industry and paved the way to expand this drug modality to new therapeutic areas. Excluding vaccines, there are five mRNA therapeutic products in clinical trial development as of November 2022.

Manufacturing 130

Manufacturing RNA Contamination Vaccination 130

Pharmaceutical Technology

JANUARY 19, 2023

The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above. Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

Pharmaceutical Technology

NOVEMBER 30, 2022

However, efficiently manufacturing the drug represents another barrier to cross before realizing the full revenue potential then successfully. Each month, Pharmaceutical Technology takes a look at recent decisions taken by regulatory and reimbursement agencies and identifies the key manufacturing players that can be impacted by them.

Manufacturing 130

Manufacturing Packaging Packaging Drugs 130

BioPharma Reporter

MARCH 22, 2021

Australiaâs Therapeutic Goods Administration (TGA) has approved manufacture of the AstraZeneca COVID-19 vaccine by CSL â Seqirus: reducing the country's dependence on limited supply from abroad and allowing a wider vaccination campaign to begin.

Vaccination 111

Vaccination Vaccine Manufacturing Regulation 111

Pharmaceutical Technology

DECEMBER 8, 2022

smart manufacturing is a way of using advanced technology ecosystems to continuously improve product quality, drive savings, and meet demands. In the pharmaceutical industry, this modern approach to manufacturing is increasingly being seen as the best way to meet the high quality requirements demanded of the industry. By Datwyler.

Manufacturing 246

Manufacturing Packaging Packaging Production 246

Pharmaceutical Technology

FEBRUARY 15, 2023

Clover Biopharmaceuticals has launched its recombinant SARS-CoV-2 subunit vaccine , a protein-based Covid-19 vaccine, in China. In December last year, Clover’s Covid-19 vaccine received emergency use authorisation in the country. 5, in a separate Phase III trial.

Vaccination 130

Vaccination Vaccine Clinical Trials Clinical Trials 130

World of DTC Marketing

JANUARY 8, 2021

SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others. So far the winners are Pfizer and Moderna. Supply Issues?

Vaccination 266

Vaccination Vaccine Pharma Companies Development 266

Pharmaceutical Technology

JUNE 2, 2023

The European Commission (EC) and Pfizer/BioNTech have agreed to amend their current supply contract to deliver Covid-19 vaccines to the EU. More significantly, the revised contract secures about 70 million vaccine doses every year from 2023 to 2026 for member states, leaving little space in the market for competitors.

Vaccination 130

Vaccination Vaccine Marketing Manufacturing 130

Pharmaceutical Technology

AUGUST 26, 2022

Amid a shortage of monkeypox vaccine doses, the WHO and FDA have declared public health emergencies, and the FDA has granted its first Emergency Use Authorization (EUA) to a monkeypox vaccine and opened the door for more. On the same day, the FDA granted a EUA to Bavarian Nordic’s (Copenhagen, Denmark) Jynneos vaccine.

Vaccination 130

Vaccination Vaccine Immune Response Manufacturing 130

Pharmaceutical Technology

MARCH 21, 2023

In such turbulent times, ensuring the most efficient and cost-effective manufacturing frameworks becomes even more important. Most pharmaceutical and biotech companies outsource certain production tasks to contract manufacturing organizations (CMOs). SK Biotek is contracted to manufacture the small molecule API.

Manufacturing 147

Manufacturing Drugs Packaging Packaging 147

BioTech 365

JANUARY 6, 2022

Vaccine Contract Manufacturing Global Market Forecast to Record Compound Annual Growth of 9% Between 2021-2026 – ResearchAndMarkets.com Vaccine Contract Manufacturing Global Market Forecast to Record Compound Annual Growth of 9% Between 2021-2026 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Vaccine Contract Manufacturing (..)

Contract Manufacturing 40

Contract Manufacturing Manufacturing Vaccination Vaccine 40

Pharmaceutical Technology

SEPTEMBER 14, 2022

Novavax and Serum Institute of India (SII) have reported that the former’s Covid-19 vaccine, NVX-CoV2373, has received full product registration from the South African Health Products Regulatory Authority (SAHPRA), with conditions. It is marketed under the brand name Covovax in the country.

Vaccination 147

Vaccination Vaccine Clinical Trials Clinical Trials 147

Pharma Mirror

OCTOBER 28, 2021

Amsterdam, The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030. The post CPhI Annual Report 2021: Short term reshoring the catalyst for longer term manufacturing innovations by 2030 appeared first on Pharma Mirror Magazine.

Manufacturing 130

Manufacturing Vaccination Vaccine Marketing 130

BioTech 365

MARCH 18, 2021

Global Viral Vector Manufacturing Market 2020-2027 – With Viral Vector-based Vaccines Used for COVID-19 in Development, Viral Vector Manufacturing Market Poised to Benefit – ResearchAndMarkets.com Global Viral Vector Manufacturing Market 2020-2027 – With Viral Vector-based Vaccines Used for COVID-19 in … Continue reading → (..)

Manufacturing 40

Manufacturing Marketing Vaccination Vaccine 40

World of DTC Marketing

MARCH 15, 2021

Pfizer, alone, is estimated to earn about $15 billion for their vaccine, and they had absolutely nothing to do with Operation Warp Speed. The study found that of the various high R&D manufacturing industries, the telephone industry retains 61% of total spending, the auto industry retains 68% and the computer industry retains 67%.

Vaccination 180

Vaccination Vaccine Development Sales 180